300356-32-5

Usage

Uses

Used in Organic Synthesis:
5-Bromo-2-(methylsulfonyl)benzotrifluoride is utilized as an intermediate compound in organic synthesis for its ability to introduce the trifluoromethyl group into other chemical structures. This property is particularly useful in the development of pharmaceuticals, agrochemicals, and other specialty chemicals where the trifluoromethyl group can enhance the stability, reactivity, or biological activity of the final product.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 5-Bromo-2-(methylsulfonyl)benzotrifluoride is used as a key intermediate in the synthesis of various drug molecules. Its unique functional groups can be strategically modified to create new compounds with improved pharmacological properties, such as increased potency, selectivity, or reduced side effects.
Used in Agrochemical Industry:
5-Bromo-2-(methylsulfonyl)benzotrifluoride is also employed in the agrochemical industry as a building block for the development of novel pesticides and herbicides. The introduction of the trifluoromethyl group can enhance the effectiveness of these compounds by improving their lipophilicity, volatility, or resistance to degradation.
Used in Specialty Chemicals:
In the specialty chemicals sector, 5-Bromo-2-(methylsulfonyl)benzotrifluoride is used as a versatile intermediate for the synthesis of various high-value compounds, such as dyes, fragrances, and functional materials. Its unique reactivity allows for the creation of new chemical entities with tailored properties for specific applications.

Upstream product

• 393-37-3 5-bromo-2-fluorobenzotrifluoride 
• 300356-31-4 (4-bromo-2-(trifluoromethyl)phenyl)(methyl)sulfane 

Downstream Products

• 648905-05-9 1-(2-{4-[2-(4-methanesulfonyl-3-methoxy-phenyl)-6-methoxy-naphthalen-1-yloxy]-phenoxy}-ethyl)-piperidine 
• 1006899-20-2 5,5-dimethyl-3-(4-(methylsulfonyl)-3-(trifluoromethyl)phenyl)imidazolidine-2,4-dione 

Relevant academic research and scientific papers

NOVEL IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES

A subject of the present application is novel imidazolidine-2, 4-dione derivatives of general formula (I) These products have an anti-proliferative activity. They are particularly useful for treating the pathological states and the diseases linked to an abnormal cell proliferation such as cancers. The invention also relates to the pharmaceutical compositions containing said products and their use for the preparation of a medicament.

NOVEL IMIDAZOLIDINE-2,4-DIONE DERIVATIVES

A subject of the present application is novel imidazolidine-2,4-dione derivatives of formula (I). These products have an anti-proliferative activity. They are particularly useful for treating the pathological states and the diseases linked to an abnormal cell proliferation such as cancers. The invention also relates to the pharmaceutical compositions containing said products and their use for the preparation of a medicament.

NAPHTHYLACETIC ACIDS

The invention is concerned with the compounds of formula (I) and pharmaceutically acceptable salts and esters thereof, wherein X, Q, and R1-R6 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

PHENOXIACETIC ACID DERIVATIVES

The invention relates to certain 2-substituted phenoxyacetic acid derivatives of formula (I), in which the variables are as defined in the claims, useful in the treatment of diseases or conditions in which modulation of the CRTh2 receptor is beneficial, s

SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP

The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.

Trans olefinic glucokinase activators

2,3-Di-substituted trans olefinic N-heteroaromatic or urido propionamides with said substitution at the 2-position being a substituted phenyl group and at the 3-position being a cycloalkyl ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.

Heteroaromatic glucokinase activators

2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 2-position being a substituted phenyl group and at the 3-position being a cycloalkyl ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.